Sponsored Content by GeneSight
According to the National Institute of Mental Health, more than 16 million people in the United States suffer from serious depression that often get worse without proper treatment.
According to the American Psychiatric Association, the goal of treatment is remission, which means patients are no longer depressed. However, half of all patients with major depression will fail to respond to their first prescribed medication, leading patients on a medication odyssey of trial-and-error treatments that can last for years.
New data from the landmark “GUIDED study” – the largest ever pharmacogenetics study of patients with depression – were published in the Journal of Psychiatric Research in January 2019.
The study demonstrated that when doctors use the GeneSight genetic test to guide medication selection patients had a: 50% improvement in remission and 30% improvement in response to treatment by week 8 compared to doctors who didn’t use the genetic test.
Importantly, remission and response rates in the GeneSight group continued to improve through week 24, demonstrating the long-term durability of the test results.
The above video and article is paid commercial program. The opinions and views expressed belong to its sponsors and are not those of Nexstar Broadcasting, Inc., this station or their affiliates or employees.